Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher, Intrinsic Bioprobes Partner to Develop Mass Spec Assays

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific and Intrinsic Bioprobes today announced an agreement to co-develop and market a mass spectrometry-based solution for researchers to do quantitative, high-throughput, and high resolution protein biomarker assays.

Under the agreement, IBI's proprietary immunoenrichment technology will be integrated with Thermo Fisher's sample handling and mass specs, providing "researchers with a more complete, higher-resolution view of the proteome," Thermo Fisher said in a statement.

Via a reseller agreement, the solution will initially be used to detect human parathyroid hormone, or PTH, and its variants, which have the potential to be used as biomarkers for bone disease and endocrinological disease.

Researchers at Thermo Fisher's Biomarkers Initiatives in Mass Spectrometry, or BRIMS, Center will collaborate with IBI to develop a mass spec immunoassay workflow for research laboratories. Thermo Fisher will market, distribute, and support the solution and the workflow.

Financial terms of the deal were not revealed.

In a statement, Mary Lopez, director of BRIMS, said the two companies have been collaborating for the past year to develop a quantitative assay for PTH and its variants. The work they've done "demonstrates a workflow that enables detection and quantification of very low abundance intact PTH, and more importantly, several novel PTH protein variants that cannot be detected using conventional assays," she said.

While mass specs can identify and quantify protein variants, researchers have been "stymied by the lack of an integrated, high-throughput mass spectrometry workflow that is robust and reproducible from laboratory to laboratory," the company added.

IBI's immunoenrichment technology is based on a patented pipette tip that integrates a high-throughput, high-binding capacity microcolumn activated with antibodies. The technology allows for the isolation and analysis of very low abundance proteins such as PTH in complex solutions. Compared to other immunoenrichment approaches, IBI's can capture more low abundance proteins, Thermo Fisher said.

Based in Tempe, Ariz., IBI develops technologies for proteomics and biomarker analysis.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.